Asterias Biotherapeutics Company Profile (NYSEMKT:AST)

About Asterias Biotherapeutics (NYSEMKT:AST)

Asterias Biotherapeutics logoAsterias Biotherapeutics, Inc. is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients' immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient's own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:AST
  • CUSIP: N/A
  • Web: asteriasbiotherapeutics.com
Capitalization:
  • Market Cap: $169.96 million
  • Outstanding Shares: 49,263,000
Average Prices:
  • 50 Day Moving Avg: $3.40
  • 200 Day Moving Avg: $3.58
  • 52 Week Range: $2.54 - $5.80
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.54
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $7.37 million
  • Price / Sales: 23.06
  • Book Value: $0.91 per share
  • Price / Book: 3.79
Profitability:
  • EBIDTA: ($28,300,000.00)
  • Net Margins: -312.79%
  • Return on Equity: -58.31%
  • Return on Assets: -42.66%
Misc:
  • Average Volume: 142,914 shs.
  • Beta: 1.58
  • Short Ratio: 20.53
 
Frequently Asked Questions for Asterias Biotherapeutics (NYSEMKT:AST)

What is Asterias Biotherapeutics' stock symbol?

Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "AST."

How were Asterias Biotherapeutics' earnings last quarter?

Asterias Biotherapeutics Inc (NYSEMKT:AST) posted its quarterly earnings results on Monday, August, 15th. The company reported ($0.12) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.19) by $0.07. The company had revenue of $1.53 million for the quarter, compared to analysts' expectations of $1.14 million. Asterias Biotherapeutics had a negative return on equity of 58.31% and a negative net margin of 312.79%. View Asterias Biotherapeutics' Earnings History.

Where is Asterias Biotherapeutics' stock going? Where will Asterias Biotherapeutics' stock price be in 2017?

2 equities research analysts have issued 1-year target prices for Asterias Biotherapeutics' shares. Their predictions range from $10.00 to $10.00. On average, they expect Asterias Biotherapeutics' stock price to reach $10.00 in the next twelve months. View Analyst Ratings for Asterias Biotherapeutics.

What are analysts saying about Asterias Biotherapeutics stock?

Here are some recent quotes from research analysts about Asterias Biotherapeutics stock:

  • 1. According to Zacks Investment Research, "Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company's technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. " (3/21/2017)
  • 2. FBR & Co analysts commented, "We are transferring coverage of Asterias Biotherapeutics, Inc. (AST) and maintaining our Outperform rating, but we are lowering our price target to $6 (from $10) to reflect a more conservative view. AST is developing therapies in an area of immense promise that can change the practice of medicine. However, the emerging field of regenerative medicine using stem cell therapy is accompanied by increased regulatory and clinical risk. The company’s lead program (AST-OPC1) is a pluripotent stem cell platform, a cell line derived from embryonic stem cells. Pluripotent stem cells are “master cells” and have the potential to differentiate into any cell type, as well as reproduce indefinitely. AST’s pluripotent stem cells, AST-OPC1, are differentiated into oligodendrocyte progenitor cells, which are glial cells in the central nervous system. AST-OPC1 is being developed for spinal cord injuries (SCIs) and is in a Phase I/IIa trial testing higher doses for safety and efficacy. There is no cure or effective therapy approved for SCI that can rehabilitate patients." (3/7/2017)

Who are some of Asterias Biotherapeutics' key competitors?

Who are Asterias Biotherapeutics' key executives?

Asterias Biotherapeutics' management team includes the folowing people:

  • Don M. Bailey, Chairman of the Board
  • Stephen L. Cartt, Director
  • Ryan Daniel Chavez, Chief Financial Officer, General Counsel
  • Jane S. Lebkowski Ph.D., Chief Scientific Officer
  • Katharine E. Spink Ph.D., Chief Operating Officer, Executive Vice President
  • Casey C. Case Ph.D., Senior Vice President - Research and Nonclinical Development
  • Edward D. Wirth III, Chief Medical Officer
  • Alfred D. Kingsley, Director
  • Aditya P. Mohanty, Director
  • Robert W. Peabody CPA, Director

How do I buy Asterias Biotherapeutics stock?

Shares of Asterias Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Asterias Biotherapeutics' stock price today?

One share of Asterias Biotherapeutics stock can currently be purchased for approximately $3.45.


MarketBeat Community Rating for Asterias Biotherapeutics (NYSEMKT AST)
Community Ranking:  2.5 out of 5 (  )
Outperform Votes:  72 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  144
MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Asterias Biotherapeutics (NYSEMKT:AST) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00

Analysts' Ratings History for Asterias Biotherapeutics (NYSEMKT:AST)
Show:
DateFirmActionRatingPrice TargetDetails
3/7/2017FBR & CoBoost Price TargetOutperform$6.00 -> $10.00View Rating Details
9/11/2016HC WainwrightReiterated RatingBuy$10.00View Rating Details
5/23/2016Chardan CapitalInitiated CoverageBuy$5.50View Rating Details
5/17/2016Rodman & RenshawReiterated RatingBuy$10.00View Rating Details
8/11/2015MLV & Co.Reiterated RatingBuy$9.00View Rating Details
(Data available from 7/23/2015 forward)

Earnings

Earnings History for Asterias Biotherapeutics (NYSEMKT:AST)
Earnings by Quarter for Asterias Biotherapeutics (NYSEMKT:AST)
Earnings History by Quarter for Asterias Biotherapeutics (NYSEMKT AST)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2016Q316($0.17)($0.24)$1.50 million$2.10 millionViewN/AView Earnings Details
8/15/2016Q216($0.19)($0.12)$1.14 million$1.53 millionViewListenView Earnings Details
5/16/2016Q116($0.14)($0.27)$1.60 millionViewListenView Earnings Details
3/29/2016Q415($0.13)($0.13)$1.07 millionViewListenView Earnings Details
11/9/2015Q315($0.11)($0.06)$1.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.11)($0.10)ViewListenView Earnings Details
5/7/2015($0.13)($0.14)ViewN/AView Earnings Details
3/10/2015($0.13)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Asterias Biotherapeutics (NYSEMKT:AST)
Current Year EPS Consensus Estimate: $-0.68 EPS
Next Year EPS Consensus Estimate: $-0.76 EPS

Dividends

Dividend History for Asterias Biotherapeutics (NYSEMKT:AST)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Asterias Biotherapeutics (NYSEMKT:AST)
Insider Trades by Quarter for Asterias Biotherapeutics (NYSEMKT:AST)
Institutional Ownership by Quarter for Asterias Biotherapeutics (NYSEMKT:AST)
Insider Trades by Quarter for Asterias Biotherapeutics (NYSEMKT:AST)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/9/2017Edward WirthInsiderSell3,415$4.60$15,709.00View SEC Filing  
1/9/2017Katharine E SpinkCOOSell4,781$4.60$21,992.60View SEC Filing  
10/6/2016Edward WirthInsiderSell3,415$4.12$14,069.80View SEC Filing  
10/6/2016Katharine E. SpinkCOOSell4,781$4.11$19,649.91View SEC Filing  
9/9/2016Edward WirthInsiderSell14,760$3.52$51,955.20View SEC Filing  
9/9/2016Katharine E. SpinkCOOSell19,336$3.52$68,062.72View SEC Filing  
6/30/2016Stephen Lahue CarttCEOBuy10,000$2.40$24,000.00View SEC Filing  
6/29/2016Richard T LebuhnDirectorBuy5,000$2.38$11,900.00View SEC Filing  
6/10/2016Stephen Lahue CarttCEOBuy50,000$2.93$146,500.00View SEC Filing  
6/9/2016Alfred D KingsleyDirectorBuy4,000$2.93$11,720.00View SEC Filing  
5/13/2016Natale S RicciardiDirectorBuy14,706$3.39$49,853.34View SEC Filing  
9/15/2015Edward WirthinsiderSell2,880$6.00$17,280.00View SEC Filing  
9/15/2015Katharine E. SpinkCOOSell3,760$6.00$22,560.00View SEC Filing  
6/25/2015Andrew ArnoDirectorBuy5,000$4.32$21,600.00View SEC Filing  
2/9/2015Pedro LichtingerCEOBuy128,205$3.90$499,999.50View SEC Filing  
10/1/2014Scarsdale Equities LlcMajor ShareholderBuy60,000$5.93$355,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Asterias Biotherapeutics (NYSEMKT:AST)
Latest Headlines for Asterias Biotherapeutics (NYSEMKT:AST)
Source:
DateHeadline
seekingalpha.com logo3 Things In Biotech You Should Learn Today: July 19, 2017
seekingalpha.com - July 19 at 10:24 PM
prnewswire.com logoAsterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-A 20 Million Cell Cohort - PR Newswire (press release)
www.prnewswire.com - July 17 at 9:45 PM
reuters.com logoBRIEF-Asterias Biotherapeutics completes enrollment and dosing of a cohort of an early-stage study
www.reuters.com - July 17 at 4:27 PM
finance.yahoo.com logoAsterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-A 20 Million Cell Cohort
finance.yahoo.com - July 17 at 4:27 PM
finance.yahoo.com logoCorporate News Blog - Asterias Announces Completion of Enrollment and Dosing for its 10 million Cell Cohort in SCiStar Study
finance.yahoo.com - July 14 at 5:56 PM
nasdaq.com logoNVS Gets Thumbs Up, Two Biosimilar Candidates To Face FDA Panel, VKTX On Track - Nasdaq
www.nasdaq.com - July 13 at 2:44 AM
prnewswire.com logoAsterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-B 10 Million Cell Cohort - PR Newswire (press release)
www.prnewswire.com - July 12 at 4:39 PM
reuters.com logoBRIEF-Asterias Biotherapeutics completes enrollment, dosing of Scistar study's AIS-B 10 mln cell cohort - Reuters
www.reuters.com - July 12 at 4:39 PM
finance.yahoo.com logoAsterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-B 10 Million Cell Cohort
finance.yahoo.com - July 12 at 4:39 PM
prnewswire.com logoAsterias Biotherapeutics Receives FDA Clearance to Enroll C-4 Patients in SCiStar Study - PR Newswire (press release)
www.prnewswire.com - July 11 at 4:01 PM
streetinsider.com logoAsterias Biotherapeutics (AST) Announces FDA Clearance to Enroll ... - StreetInsider.com
www.streetinsider.com - July 10 at 9:10 PM
reuters.com logoBRIEF-Asterias Biotherapeutics receives FDA clearance to enroll C-4 patients in study - Reuters
www.reuters.com - July 10 at 9:10 PM
reuters.com logoBRIEF-Asterias Biotherapeutics receives FDA clearance to enroll C-4 patients in study
www.reuters.com - July 10 at 4:07 PM
finance.yahoo.com logoAsterias Biotherapeutics Receives FDA Clearance to Enroll C-4 Patients in SCiStar Study
finance.yahoo.com - July 10 at 4:06 PM
businesswire.com logoBiotime Expands & Advances Ophthalmology Portfolio
www.businesswire.com - June 19 at 8:57 AM
nasdaq.com logoHadasit Bio-Holdings (HBL) and BioTime Complete Shares Swap Transaction in Cellcure Neurosciences
www.nasdaq.com - June 19 at 8:57 AM
reuters.com logoBRIEF-Asterias Biotherapeutics Inc board increased number of members on board from nine to ten - Reuters
www.reuters.com - June 17 at 3:45 PM
prnewswire.com logoPatients with Complete Paralysis Show Additional Recovery of Arm ... - PR Newswire (press release)
www.prnewswire.com - June 13 at 6:23 PM
reuters.com logoBRIEF-Asterias presents 9-month follow-up data from ongoing trial
www.reuters.com - June 13 at 1:23 PM
prnewswire.com logoAsterias Biotherapeutics to Present New 9-Month Efficacy Data from AST-OPC1 SCiStar Study at the International ... - PR Newswire (press release)
www.prnewswire.com - June 9 at 4:00 PM
businesswire.com logoBioTime to Announce Top Line Data From the Company’s Renevia European Pivotal trial
www.businesswire.com - June 8 at 4:22 PM
finance.yahoo.com logoAsterias Biotherapeutics to Present New 9-Month Efficacy Data from AST-OPC1 SCiStar Study at the International Society for Stem Cell Research (ISSCR) 2017 Annual Meeting
finance.yahoo.com - June 8 at 8:15 AM
finance.yahoo.com logoAsterias Biotherapeutics, Inc. :AST-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 4:57 PM
prnewswire.com logoAsterias Biotherapeutics Announces Top Leadership Transition - PR Newswire (press release)
www.prnewswire.com - May 25 at 9:32 PM
finance.yahoo.com logoAsterias Biotherapeutics Announces Top Leadership Transition
finance.yahoo.com - May 24 at 9:29 AM
prnewswire.com logoAsterias Biotherapeutics Reports First Quarter Financial Results and Recent Development Progress - PR Newswire (press release)
www.prnewswire.com - May 12 at 4:16 PM
reuters.com logoBRIEF-Asterias Biotherapeutics announced new positive serial magnetic resonance imaging data
www.reuters.com - May 11 at 4:06 PM
finance.yahoo.com logoNew MRI Data from Asterias' Ongoing SCiStar Clinical Study Indicates AST-OPC1 Cells Prevent Formation of Damaging Lesion Cavities in Patients Suffering Severe Spinal Cord Injury
finance.yahoo.com - May 11 at 4:06 PM
finance.yahoo.com logoAsterias Biotherapeutics Reports First Quarter Financial Results and Recent Development Progress
finance.yahoo.com - May 11 at 4:06 PM
prnewswire.com logoAsterias Biotherapeutics to Report First Quarter Results on May 11 ... - PR Newswire (press release)
www.prnewswire.com - May 4 at 3:46 PM
finance.yahoo.com logoAsterias Biotherapeutics to Report First Quarter Results on May 11, 2017
finance.yahoo.com - May 4 at 3:46 PM
finance.yahoo.com logoPresidential Symposium at the American Society of Gene and Cell Therapy (ASGCT) 20th Annual Meeting Will Feature Presentation on Asterias' AST-OPC1 for Spinal Cord Injury
finance.yahoo.com - May 3 at 10:35 AM
seekingalpha.com logoBioTime Inc.: Sifting Through Numerous Trials For Potential Opportunities
seekingalpha.com - May 1 at 3:40 PM
prnewswire.com logoAsterias Biotherapeutics Announces Data Monitoring Committee Unanimously Recommends Continuation of SCiStar ... - PR Newswire (press release)
www.prnewswire.com - April 27 at 4:06 PM
streetinsider.com logoAsterias Biotherapeutics (AST) Reports Publication of Positive Phase 2 Data on AST-VAC1 to Treat AML - StreetInsider.com
www.streetinsider.com - April 27 at 4:06 PM
rttnews.com logoAKBA Jumps On Otsuka Deal, MNOV Abuzz, CAPR Counting On HOPE...
www.rttnews.com - April 26 at 9:49 AM
reuters.com logoBRIEF-Asterias publishes positive Phase 2 data on AST-VAC1 for the treatment of acute myeloid leukemia
www.reuters.com - April 26 at 9:49 AM
finance.yahoo.com logoAsterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia (AML) in 'Cancer'
finance.yahoo.com - April 26 at 9:49 AM
streetinsider.com logoAsterias Biotherapeutics (AST) Says DMC Unanimously Recommends Continuation of SCiStar Phase 1/2a Trial of AST ... - StreetInsider.com
www.streetinsider.com - April 25 at 3:38 PM
finance.yahoo.com logoAsterias Biotherapeutics Announces Data Monitoring Committee Unanimously Recommends Continuation of SCiStar …
finance.yahoo.com - April 25 at 11:21 AM
finance.yahoo.com logoImplied Volatility Surging for Asterias Biotherapeutics (AST) Stock Options
finance.yahoo.com - April 24 at 10:32 AM
finance.yahoo.com logoETFs with exposure to Asterias Biotherapeutics, Inc. : April 17, 2017
finance.yahoo.com - April 17 at 3:37 PM
finance.yahoo.com logoETFs with exposure to Asterias Biotherapeutics, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 8:08 AM
finance.yahoo.com logoASTERIAS BIOTHERAPEUTICS, INC. Financials
finance.yahoo.com - April 1 at 3:44 PM
prnewswire.com logoAsterias Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent ... - PR Newswire (press release)
www.prnewswire.com - March 29 at 12:54 PM
us.rd.yahoo.com logoAsterias Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Development Progress
us.rd.yahoo.com - March 28 at 8:40 PM
businesswire.com logoKey BioTime Patents Upheld by European Patent Office
www.businesswire.com - March 28 at 10:56 AM
biz.yahoo.com logoQ4 2016 Asterias Biotherapeutics Inc Earnings Release - After Market Close
biz.yahoo.com - March 28 at 10:56 AM
americanbankingnews.com logoAsterias Biotherapeutics Inc (AST) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 27 at 8:35 AM
americanbankingnews.com logoZacks Investment Research Upgrades Asterias Biotherapeutics Inc (AST) to "Buy"
www.americanbankingnews.com - March 21 at 5:01 PM

Social

This page was last updated on 7/23/2017 by MarketBeat.com Staff